Welcome to our dedicated page for Grace Therapeutics SEC filings (Ticker: GRCE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Grace Therapeutics, Inc. filings document material events, operating updates and governance matters for a late-stage biopharma company advancing GTx-104. Form 8-K disclosures cover quarterly results, corporate presentations, the GTx-104 New Drug Application, the FDA Complete Response Letter, and the chemistry, manufacturing and controls and non-clinical subjects cited in that regulatory correspondence.
The filing record also includes disclosures on patent protection for “Nimodipine Parenteral Administration,” exercises and expirations of common warrants issued in private placements, exhibit-based press releases, and amendments to executive letter agreements and compensation arrangements.
Grace Therapeutics, Inc. (Nasdaq: GRCE) has filed its Form 10-K for the fiscal year ended 31 March 2025. The company remains a non-accelerated filer and smaller reporting company, indicating a market capitalization below SEC thresholds; non-affiliate market value was $24.0 million as of 30 September 2024. A total of 13,828,562 common shares were outstanding on 19 June 2025.
The filing reiterates management’s strategy to build a late-stage pharmaceutical business focused on rare and orphan diseases through its proprietary drug-delivery technologies. Development resources are being prioritized toward lead candidate GTx-104, an intravenous formulation of nimodipine intended to manage hypotension in aneurysmal subarachnoid hemorrhage patients via the FDA’s 505(b)(2) pathway, with potential orphan-drug exclusivity. GTx-102 (Ataxia Telangiectasia) and GTx-101 (post-herpetic neuralgia) have been de-prioritized; management will seek licensing or sale opportunities for these assets.
The forward-looking statements section outlines numerous operational and regulatory assumptions, including dependence on third-party CROs/CMOs, patent strategy, and the need for additional financing. Key risks cited are (i) single-asset dependency on GTx-104, (ii) clinical failure risks inherent in rare-disease drug development, (iii) reimbursement uncertainty, (iv) absence of internal manufacturing capabilities, and (v) intellectual-property challenges.
No income-statement, balance-sheet or cash-flow tables are provided in the excerpt, and the company has not yet secured commercial revenue. The report confirms ongoing SEC compliance (all reports filed, all XBRL data submitted) and that the auditor did not provide an attestation of internal control over financial reporting under SOX 404(b), consistent with its filer status.